

UK Cystic Fibrosis Registry 2025 Annual Data Report

At a glance

This 'at a glance' version of the UK Cystic Fibrosis Registry Annual Data Report 2025 highlights some key information about people with cystic fibrosis (CF) in the UK who had an annual review in 2025. For more detail, see the full report at cysticfibrosis.org.uk/registry

Number of people with CF in 2025

11,610

registered* people

* People who have had at least one encounter or annual review recorded in the current year or the past two years and people newly consented to the Registry.



Births



102 women
with CF had
babies in 2025



31 men with CF
became fathers
in 2025




152 new diagnoses
in 2025

107 of these were identified
by new born screening

7,018

people with CF
are 16 years
or older.



Ethnicity

White **94.4%**

Asian **3.4%**

Black **0.3%**


Mixed **1.3%**

Other **0.6%**

* % of those with known ethnic group recorded

Lung health outcomes in 2019 and 2025


Median FEV₁% predicted at annual review




FEV₁% is reported for people who have not had a lung transplant, using GLI global equations. 10 year olds with CF have a median FEV₁% predicted of 101% in 2025. A median FEV₁% predicted of 100% means their lung function is on average the same as for comparable people without CF.

Lung infections and respiratory culture samples 2019 and 2025


Age under 16 years



Age 16+ years




Respiratory support



* age 18+ years

Supplemental feeding



* enteral and parenteral feeding

Complications in 2019 and 2025

CF diabetes*

Age 10** to 15 years

13.1%



2019

8.4%



2025

Age 16+ years

33.9%



2019

32.5%




2025


* on treatment for CF diabetes

** in 2019 and 2025, approx 1% of people under 10 years had CF diabetes


Liver and Gastrointestinal complications




Respiratory related complications



Primary airway clearance



2019



2025

- Exercise
- Any airway clearance technique (ACT)*
- None


* includes all varieties of ACT inc. breathing ex, manual techniques and devices

Medications and other treatments

Intravenous antibiotics (IV) in 2019 and 2025


44.5%

of people had at least one course of IV antibiotics (at home or in hospital) in **2019**



18.1%

of people had at least one course of IV antibiotics (at home or in hospital) in **2025**



The proportion of people taking all 3 types of inhaled medication has fallen from 22% in 2019 to 10.3% in 2025.




Inhaled medication therapy in 2025


The Venn diagram shows how many people with CF are on one or more of some inhaled therapies and the combinations they take.

None of these inhaled medications: 3,448 (32.5%)


- Inhaled antibiotics
- DNase
- Hypertonic saline or mannitol



CFTR modulators (CFTRm) use in 2025



Proportion of people who have never used a CFTR modulator 2021-2025



People may never have been on a CFTRm for one of many reasons including: ineligibility, living with a transplant or a decision made between an individual and their care team



For more information about the UK Cystic Fibrosis Registry please visit our website cysticfibrosis.org.uk/registry

To read the full Registry Annual report data please scan the QR code.